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Abstract 
Objective:  
Cardiovascular disease (CVD) is the most prevalent cause of mortality among patients with 
Type 1 or Type 2 diabetes, due to accelerated atherosclerosis. Recent evidence suggests a 
strong link between atherosclerosis and insulin resistance due to impaired insulin receptor 
(IR) signaling. Moreover, inflammatory cells, in particular macrophages, play a key role in 
pathogenesis of atherosclerosis and insulin resistance in humans. We hypothesised that 
inhibiting the activity of protein tyrosine phosphatase 1B (PTP1B), the major negative 
regulator of the IR, specifically in macrophages, would have beneficial anti-inflammatory 
effects and lead to protection against atherosclerosis and CVD.  
Methods: 
We generated novel macrophage-specific PTP1B knockout mice on atherogenic 
background (ApoE-/-/LysM-PTP1B). Mice were fed standard or pro-atherogenic diet, and 
body weight, adiposity (echoMRI), glucose homeostasis, atherosclerotic plaque 
development, and molecular, biochemical and targeted lipidomic eicosanoid analyses were 
performed.  
Results:  
Myeloid-PTP1B knockout mice on atherogenic background (ApoE-/-/LysM-PTP1B) exhibited 
a striking improvement in glucose homeostasis, decreased circulating lipids and decreased 
atherosclerotic plaque lesions, in the absence of body weight/adiposity differences. This was 
associated with enhanced phosphorylation of aortic Akt, AMPKα and increased secretion of 
circulating anti-inflammatory cytokine interleukin-10 (IL-10) and prostaglandin E2 (PGE2), 
without measurable alterations in IR phosphorylation, suggesting a direct beneficial effect of 
myeloid-PTP1B targeting.  
Conclusions:  
Here we demonstrate that inhibiting the activity of PTP1B specifically in myeloid lineage cells 
protects against atherosclerotic plaque formation, under atherogenic conditions, in an ApoE-/- 
mouse model of atherosclerosis. Our findings suggest for the first time that macrophage 
PTP1B targeting could be a therapeutic target for atherosclerosis treatment and reduction of 
CVD risk.  
Keywords: 
PTP1B, insulin resistance, interleukin-10, AMPK, atherosclerosis. 
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1. Introduction 
Despite extensive research and major advancements in modern medicine, CVDs are still the 
leading cause of death worldwide accounting for 17.3 million deaths globally per year (WHO 
Statistics, http://www.who.int/mediacentre/factsheets/fs317/en/). Such diseases are 
exacerbated by obesity and secondary pathologies such as Type 2 diabetes and 
atherosclerosis [1]; therefore, it is not surprising that the number of deaths attributed to 
CVDs is expected to rise within the next decade. Atherosclerosis is an inflammatory disease 
of the large and medium-sized arteries, and it is typically characterized by formation of 
lesions, which can lead to arterial thrombosis and ischemic injury. The proposed 
mechanisms that link accelerated atherosclerosis and increased cardiovascular risk in 
diabetic and obese patients are poorly understood. It has been suggested that an 
association between hyperglycaemia and intracellular metabolic changes can result in 
oxidative stress, low-grade inflammation, and endothelial dysfunction [2].  Insulin resistance 
has also been implicated in the pathogenesis of atherosclerosis adding a further layer of 
complexity [2]. A better understanding of the mechanisms controlling these diseases is 
needed, and more targeted and effective therapeutics are urgently sought.  
In mice, deletion of the insulin receptor (IR) from vascular endothelial cells in the 
apolipoprotein-E-deficient mice (ApoE-/-) leads to an increased rate of atherosclerosis 
development [3]. Moreover ApoE-/- mice with a heterozygous deletion of the IR and its 
downstream target, Insulin Receptor Substrate 1 (IRS1), also develop accelerated 
atherosclerosis [4], as well as mice lacking insulin receptor substrate 2 (IRS2-/-) [5].  
Furthermore, decreased insulin signaling in non-hematopoietic cells, as achieved by 
transplantation of ApoE-/- mouse model of atherosclerosis with bone marrow cells from 
IRS1+/- IR+/- ApoE-/- mice, contributed to increased atherogenesis in these mice [4]. In all 
these disorders, macrophages play a key role driving the pathology [6-9]; therefore, targeting 
their activity could prove effective. 
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Protein tyrosine phosphatase (PTP)1B has been identified as the major negative regulator of 
the IR itself [10]. In mice, whole body PTP1B-/- studies established PTP1B as a major 
regulator of insulin sensitivity and body mass, via inhibition of insulin and leptin signaling, 
respectively [11,12]. Our recent research found that deletion of protein tyrosine phosphatase 
1B (PTP1B) within the myeloid cell lineage led to protection against high-fat diet (HFD)-
induced and bacterial toxin (lipopolysaccharide LPS)-induced inflammation and 
hyperinsulinemia, due to increased anti-inflammatory IL-10 and decreased pro-inflammatory 
TNFα cytokine secretion in vivo [13]. Therefore, we hypothesised that inhibiting the activity 
of PTP1B specifically in macrophages, through genetic deletion, would have beneficial anti-
inflammatory effects and lead to protection against atherosclerosis. To assess this, we used 
the ApoE-/- mouse model of atherosclerosis under physiological and atherogenic conditions.  
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2. RESEARCH DESIGN AND METHODS 
2.1 Animal studies. All animal procedures were performed under a project license approved 
by the U.K. Home Office under the Animals (Scientific Procedures) Act 1986 (PPL 60/3951). 
ApoE-/- mice were bred in house, and crosses were generated by breeding ApoE-/- to mice 
devoid of myeloid PTP1B (PTP1B-LysMCre as previously described [14]) to generate ApoE-/-
/LysM-PTP1B. At 12 weeks of age, male and female ApoE-/- and ApoE-/-/LysM-PTP1B mice 
were group housed (n=3-6 per cage) and placed on either chow or high fat diet (HFD 42% 
from fat, 0.2% cholesterol, Envigo, Huntingdon UK) for 12 weeks. Mice were maintained at 
22–24°C on 12-h light/dark cycle with free access t o food/water. At week 12, mice were 
fasted for 5h and injected with either saline or insulin (10 mU/g body weight) for 10 mins 
prior to culling by CO2 inhalation and subsequent cervical dislocation. Heart and aortic 
tissues were harvested and collected for further analysis. Tissues for subsequent western 
blot or qPCR analysis were frozen in liquid nitrogen and stored at -80°C until needed, 
whereas tissues for histology were immersed in formalin for 24h at 4°C, then stored at 4°C in 
PBS until analyzed. 
2.2 Glucose and Insulin Tolerance Tests. Mice were fasted for 5h prior to commencement 
of glucose or insulin tolerance tests (GTT and ITT, respectively). Briefly, baseline glucose 
levels were sampled from tail blood using glucose meters (AlphaTRAK, Abbott Laboratories, 
Abbot Park, IL, USA). Subsequently mice were injected I.P. with 20% glucose (w/v) or insulin 
(0.75mU/g body weight) and blood glucose measured at 15, 30, 60, and 90 mins post-
injection.   
2.3 Body Fat Mass Composition. The body composition of each mouse was analyzed 
using an Echo MRI-3-in-1 scanner (Echo Medical Systems, Houston, TX, USA). Mice were 
placed individually into a plastic tube and inserted into the scanner where total body fat and 
lean mass were determined.  
2.4 Isolation and Maturation of Bone Marrow Derived Macrophages. 
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Bone marrow derived macrophages (BMDMs) were isolated and cultured as previously 
described [13]. Briefly, following cervical dislocation, the bone marrow was flushed from the 
femurs and tibiae using sterile phosphate buffered saline (PBS, Gibco) to disrupt the bone 
marrow plugs and passed through a cell strainer. The cells were then centrifuged at 1800 g 
for 5 min and resuspended in red blood cell lysis buffer before the reaction quenched with 
PBS and respun to pellet cells. Cells were counted and seeded onto 6 well plates, at a 
density of 2 million per well, and cultured in complete media (DMEM (Gibco), 10% FBS 
(Invitrogen, Paisley, UK), 100 U/ml penicillin (Gibco) and 100 mg/ml streptomycin (Gibco)) 
supplemented with 20% L929-cell conditioned medium) for 6 days (media was replaced on 
day 3) and maintained at 37°C in a humidified atmos phere with 5% CO2. Mature 
macrophages were harvested on day 6 for subsequent experiments. 
2.5 Immunoblotting. Frozen aorta tissues were homogenized in 300µl of ice-cold 
Radioimmunoprecipitation assay (RIPA) buffer (10mM Tris-HCl pH 7.4, 150mM NaCl, 5mM 
EDTA pH 8.0, 1mM NaF, 0.1% SDS, 1% Triton X-100, 1% Sodium Deoxycholate with 
freshly added 1mM NaVO4 and protease inhibitors) using a PowerGen 125 homogenizer 
and lysates normalized to 1µg per 1µl. Proteins were separated on a 4-12% Bis-Tris gel by 
SDS-PAGE and transferred onto nitrocellulose membrane. Membranes were probed for the 
following; p-IR (Tyr 1162/1163), IR β-chain, p-AKT (Ser 473), p-p38 (The 181/Tyr 182), total 
p-38 p-S6 (Ser 235/236), total S6, p-AMPKα (Thr 172), total AMPKα, PTP1B and GAPDH. 
2.6 Histology. Immediately following cervical dislocation, hearts were immersed in formalin 
and stored at 4°C for 24hrs before being transferre d to PBS until further analysis. Hearts 
were bisected to remove the lower ventricles, frozen in OCT and subsequently sectioned at 
5μm intervals until the aortic sinus was reached. Sections were mounted and stained with oil 
red O to assess plaque formation. Images were captured using a light microscope and 
plaque formation quantified using Image J software. 
2.7 Serum Analysis. Blood was collected during terminal procedures after fasting (5hrs) 
and spun to isolate serum, then stored at -80°C. Se rum samples were subsequently 
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analyzed for insulin and IL10 levels using ELISAs (Millipore and R&D Systems, respectively) 
or total cholesterol and triglycerides (Sigma). For eicosanoid analysis, PGE2 was extracted 
from serum in methanol and isolated by C18 solid-phase extraction chromatography. PGE2-
d4 (Cayman Chemicals, Ann Arbor, MI, USA) was added to the experimental system as an 
internal standard. PGE2 was analyzed by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) using a TSQ Quantum Ultra triple quadrupole mass spectrometer coupled to an 
Accela 1250 UHPLC system (Thermo Scientific, Hemel Hempstead, UK) in negative ion 
mode with a C18 column and methanol-water gradient. Quantification was performed using 
the multiple reaction monitoring (MRM) mode using the transitions PGE2 (351→271) and 
PGE2-d4 (355→193). The concentration of PGE2 was determined by comparison to a 
calibration curve run in parallel. 
 
2.8 Statistical Analysis. We expressed all values as mean ± S.E.M. We determined group 
sizes by performing a power calculation to lead to an 80% chance of detecting a significant 
difference (P ≤ 0.05). For both in vivo and ex vivo data, each n value corresponds to a single 
mouse. Statistical analyses were performed by using one-way or Two-way ANOVA followed 
by Tukey's or Dunnett's multiple-comparison tests to compare the means of three or more 
groups or by an unpaired two-tailed Student's t-test to compare the means of two groups. 
Variances were similar between groups. In all figures, */#p≤0.05, **/##p≤0.01, ***/###p≤0.001, 
****p≤0.0001. All analyses were performed using GraphPad Prism (GraphPad Software). 
3. Results 
3.1 Myeloid specific PTP1B knockout mice exhibit improved glucose homeostasis 
independently of alterations in body weight/adiposity.  
We recently demonstrated that myeloid PTP1B (LysM PTP1B) deletion protected against 
LPS-induced inflammation and led to increased production of the anti-inflammatory cytokine 
interleukin 10 (IL-10) [14]. This intriguing finding compliments numerous studies implicating 
IL-10 as having a protective role in atherogenesis and CVD (reviewed in [15]). Given the 
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importance of myeloid cells, particularly macrophages, in the pathogenesis of both 
atherosclerosis and insulin signaling, we sought to determine if PTP1B deletion in these cells 
would have beneficial protective effects against atherosclerosis development. To achieve 
this, we generated novel myeloid-specific PTP1B knockout mice using an atherogenic 
mouse model (ApoE-/-/LysM-PTP1B) to address this. These mice developed normally and 
did not display any defects. To confirm myeloid deletion, BMDMs from ApoE-/- and ApoE-/-
/LysM-PTP1B were harvested and probed for protein expression of PTP1B (Figure 1A). 
Myeloid-specific PTP1B knockout mice on an atherogenic background (LysM-PTP1B/ApoE-/-
) were placed on HFD for 12 weeks or chow as a control. During this time, weight gain, body 
composition, glucose tolerance, and insulin tolerance were assessed in both male and 
female mice from each genotype (Figure 1B). In contrast to global PTP1B deletion [11], 
there were no differences in weight gain or body composition between genotypes in either, 
male or female mice fed a HFD (Figure 1C, E, G and Figure 1D, F, H respectively) or chow 
(Supplemental Figure1 A, B). As expected, male mice weighed more than females with the 
greatest differences seen in lean mass (Figure 1 G, H), rather than fat mass (Figure 1 E, F), 
and gained more weight over time. Despite no differences in weight gain, ApoE-/-/LysM-
PTP1B animals exhibited markedly improved glucose tolerance when compared to ApoE-/-, 
which was more pronounced in the female mice (Figure 2A, B). This improved glucose 
handling was maintained at 6 (Figure 2C, D) and 12 weeks (Figure 2E, F) of HFD and again 
more pronounced in females. When aged, 6 month old ApoE-/-/LysM-PTP1B chow fed mice 
still exhibited improved glucose handling when compared to ApoE-/- mice (Supplemental 
Figure 1C, D), in the absence of body weight changes (Supplemental Figure 1 A, B).  
Moreover, there was no difference between genotypes in HFD cohorts when subjected to 
insulin tolerance tests (Figure 2G, H) nor in circulating insulin levels (Figure 2I, J). The lack 
of difference in circulating insulin levels was also observed in chow-fed mice regardless of 
gender or genotype (Supplemental Figure 1 E, F). Given these data, the improved glucose 
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homeostasis could not be attributed to differences in weight/adiposity and instead due to 
myeloid-specific PTP1B deficiency.  
3.2 Myeloid PTP1B deficiency on ApoE-/- background results in decreased cholesterol 
and triglyceride levels and protection against diet-induced increase in atherosclerotic 
plaque area.  
Plaque formation in atherosclerosis is associated with lipid accumulation within the vessels 
and arterial walls. Current treatments include the use of lipid lowering drugs such as statins, 
which serve to reduce levels within the blood. We found that total serum cholesterol was 
decreased in ApoE-/-/LysM-PTP1B female mice in both, HFD (Figure 3A) and chow-fed 
(Supplemental Figure 2A) cohorts, whereas triglyceride levels were significantly decreased 
in female chow-fed (Supplemental Figure 2B) and male HFD-fed (Figure 3B) ApoE-/-/LysM-
PTP1B mice.   
The ultimate goal of this study was to test whether myeloid PTP1B deficiency was sufficient 
to protect against atherosclerotic plaque formation. To assess this, sections of aorta, 
beginning at the aortic root, were mounted and stained with Oil Red O. This revealed that 
there was significantly less plaque formation in ApoE-/-/LysM-PTP1B mice when compared to 
ApoE-/- HFD mice, both in male and female mice, although more prominent in females 
(Figure 3 C, D). Therefore, we demonstrate for the first time that myeloid-PTP1B deficiency 
alone is sufficient to prevent atherosclerotic plaque formation under obesogenic, HFD-
feeding condition, on an atherogenic ApoE-/- background. 
3.3 Myeloid PTP1B deficiency on ApoE-/- background results in increased PGE2 and IL-
10 secretion.  
Since we initially hypothesized that increased IL-10 levels associated with myeloid-
PTP1B deficiency may create an anti-inflammatory environment and lead to protection 
against atherosclerosis development, we next determined circulating levels of IL-10 in ApoE-
/-/LysM-PTP1B and ApoE-/- controls on chow and HFD. In agreement with our hypothesis, 
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whilst only one of the ApoE-/- controls had any detectable circulating IL-10 serum levels, IL-
10 secretion was increased in ApoE-/-/LysM-PTP1B, male and female, HFD-fed mice (Figure 
3E). Similar data was observed in the aged chow-fed ApoE-/-/LysM-PTP1B females 
(Supplementary Figure 2C). In addition, when male and female data were combined, chow-
fed ApoE-/-/LysM-PTP1B exhibited a significant increase in circulating levels of the 
eicosanoid, prostaglandin E2 (PGE2) (Figure 3F) which has been recently implicated as 
essential in switching macrophages from a pro-inflammatory M1 to an anti-inflammatory M2 
phenotype by stimulating IL-10 release [16-17]. Although not significant, a similar trend was 
observed when the groups were separated by gender (Supplemental Figure 2D).  In keeping 
with a decrease in pro-inflammatory signaling, we investigated the expression of genes 
important in the inflammatory response. More specifically, atherosclerotic plaque 
development is catalyzed by an infiltration of leukocytes to the aortic tissues. Such events 
are facilitated by monocyte chemoattractant protein-1 (MCP-1) and adhesion molecules 
including intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), that serve to recruit monocytes and facilitate their transmigration into 
the vasculature, respectively [5]. To assess whether changes in the expression of these 
genes within ApoE-/-/LysM-PTP1B mice could account for the decrease in plaque formation, 
we determined levels in aortic tissue from our mouse groups (Supplemental Figure 2). While 
there were no differences in aortic MCP-1 expression levels, ICAM levels were higher in 
male HFD-fed ApoE-/-/LysM-PTP1B mice in comparison to chow-fed ApoE-/-/LysM-PTP1B 
mice (Supplemental Figure 3A) whilst VCAM-1 levels were upregulated in HFD-fed male 
ApoE-/-/LysM-PTP1B mice in comparison to ApoE-/- mice (Supplemental Figure 3 C). In 
contrast, no significant increases were seen in the female ApoE-/-/LysM-PTP1B mice, 
suggesting a less pro-inflammatory environment in female mice, which could explain the 
more pronounced reduction in plaque formation when compared to female ApoE-/- controls. 
3.4 Myeloid PTP1B deficiency on ApoE-/- background is associated with 
hyperphosphorylation of Akt and AMPKα1 in the aorta. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
Previous studies using ApoE-/- mice heterozygous for both IR and the insulin receptor 
substrate-1 (IRS1) protein found that the apolipoprotein-E deficiency resulted in increased 
atherosclerosis development [4]. A similar phenotype was noted when IRS2 was deleted 
within the same ApoE-/- background [5]. Given these data, we hypothesised that an 
upregulation of IR signaling and associated downstream pathways could account for the 
beneficial effects of PTP1B deletion in our study. Therefore, we investigated the IR signaling 
pathway in aortic tissues. In contrast to our hypothesis, there were no detectable differences 
in phosphorylation of the IR itself in aortic tissue from either chow-fed (Figure 4A, C,  F, H) or 
HFD-fed (Figure 4B, C, G, H) ApoE-/-/LysM-PTP1B and ApoE-/- mice. However, there was a 
striking enhancement of downstream signaling, as indicated by hyperphosphorylation of Akt, 
in both male and female ApoE-/-/LysM-PTP1B mice (Figure 4A, B, D & F, G, I). As expected, 
HFD-feeding resulted in a blunted response to insulin-stimulated Akt phosphorylation in both 
males (Figure 4D) and females (Figure 4I), and in females, insulin was able to stimulate Akt 
phosphorylation only in ApoE-/-/LysM-PTP1B mice (Figure 4I). Male ApoE-/-/LysM-PTP1B 
mice also exhibited enhanced pS6 signaling (Supplemental Figure. 3 A, B, C & F, G, H). 
Considering that IL10 has recently been shown to directly phosphorylate and activate 
AMPKa [18]. and that IL10 secretion is upregulated in ApoE-/-/LysM-PTP1B mice, we 
postulated that these mice may exhibit alterations in AMPKα activation. Consistent with this 
notion, AMPKα activation in male chow fed aortic tissue was upregulated under basal 
condition in ApoE-/-/LysM-PTP1B mice (Figure 4 A, E), and pAMPKα signaling was 
enhanced in female chow and HFD-fed insulin-stimulated ApoE-/-/LysM-PTP1B mice (Figure 
4A, B, E & F, G, J). These data suggest that myeloid-PTP1B deficiency induces-AMPK 
activation. We observed no differences in p38 phosphorylation across genotype or gender 
(Supplemental Figure 4 A, B, F, G). Furthermore, there were no differences in aortic-PTP1B 
protein levels as expected and consistent with myeloid-specific PTP1B deficiency 
(Supplemental Figure 3 E, J). Therefore, since the deletion is limited to the myeloid cell 
lineage, the increase in aortic Akt and AMPKα phosphorylation can be attributed solely to 
myeloid-specific PTP1B deficiency.   
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4. Discussion 
In conclusion, we demonstrate here, that myeloid-specific genetic deletion of PTP1B 
in the ApoE-/- mouse model of atherosclerosis leads to protection against atherosclerosis 
development, suggesting beneficial effects of PTP1B inhibition for the reduction of 
cardiovascular risk and treatment of CVDs. We present evidence that myeloid-PTP1B 
deficiency results in activation of aortic Akt and AMPKα1, without measurable alterations in 
insulin receptor phosphorylation. We also demonstrate that myeloid-specific PTP1B 
deficiency on an ApoE-/- background leads to improved glucose maintenance, 
independently of body weight/adiposity differences, and that this results in increased 
circulating levels of the anti-inflammatory cytokine IL-10, and the vasodilator eicosanoid 
PGE2. Finally, we present evidence, for the first time, that demonstrates that myeloid-
PTP1B targeting results in a decrease in circulating serum cholesterol (female mice under 
chow and HFD-feeding conditions) and triglyceride levels (female mice on chow diet and 
male mice on HFD diet) and protection against atherosclerotic plaque formation.  
Our data compliment a recent study by Kandadi et al [19] that found whole body 
PTP1B deletion improved cardiomyocyte contractility in mice fed HFD, through an AMPK-
dependent mechanism. Furthermore, myeloid-specific deletion of AMPKα1 on an LDLR-/- 
mouse background, resulted in hypercholesterolemia, increased macrophage inflammation 
and plaque infiltration and exacerbated atherogenesis [20].  Thus, the increase we observe 
in aortic AMPKα1 phosphorylation with myeloid-PTP1B deficiency, and associated 
protection against atherosclerotic plaque accumulation, suggest that PTP1B inhibition may 
be anti-atherogenic through an AMPKα1-driven mechanism and warrants investigation in 
future studies.   
In further support of PTP1B inhibition as a potential therapeutic target for 
atherosclerosis, we have previously demonstrated that hepatic-PTP1B deficiency was 
sufficient to protect against HFD-induced endothelial dysfunction, in the absence of any 
changes in body mass/adiposity [21]. Considering that endothelial dysfunction acts as an 
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independent predictor of cardiovascular events, this was firm evidence that PTP1B 
inhibition may not only play an anti-diabetic role, but also hold potential for treatment of 
CVDs.  
Critically, atherosclerosis is now well regarded as a chronic inflammatory disease 
with current anti-inflammatory therapeutics aimed at targeting specific parts of the cascade 
[22].  Moreover, recent studies have focused on macrophages and, in particular, promotion 
from pro-inflammation to pro-resolution, as a means to reduce atherogenesis and similar 
chronic inflammatory pathologies [23,24].  Indeed, the anti-inflammatory cytokine IL-10, 
which promotes resolution by stimulating efferocytosis and tissue repair, is now being 
engineered as nanoparticles to allow more specific targeting, and has resulted in the 
stabilisation of the fibrous cap and necrotic core reduction in HFD-fed LDLR-/- mice [25]. 
Furthermore, a recent study by Zhu et al [18] found that IL-10 stimulation of AMPKα 
phosphorylation and subsequent downstream PI3K/Akt/mTORC1 signaling was critical for 
eliciting the anti-inflammatory properties of this cytokine. In support of these data, a 
previous study from our lab found myeloid-deletion of PTP1B resulted in increased anti-
inflammatory signaling, as evidenced by a decrease in pro-inflammatory IL-6 and TNFα, 
and an increase in pro-resolution IL-10 [14].  
Our targeted lipidomic eicosanoid analysis revealed a specific increase in circulating 
PGE2 levels; an eicosanoid essential in eliciting the pro-inflammatory cascade. In contrast 
to its role as a pro-inflammatory molecule, recent research has implicated PGE2 to behave 
as an immunomodulator, acting on four distinct G-protein coupled receptors (GPCRs, EP1-
4) to both, inhibit and stimulate, the synthesis of pro- and anti-inflammatory cytokines, 
respectively. Importantly, PGE2 has been found to be essential in switching macrophages 
from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype and does so through an 
IL-10 dependent mechanism [16,17]. In addition, deletion of PTP1B enhances the 
expression of COX2, which is upstream of PGE2 release [26], and was found to be 
protective against endothelial dysfunction in a model of Type 1 diabetes.  Finally, PGE2 has 
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been implicated in providing a protective role in diet-induced obesity and metabolic 
syndrome, critical for white to brown fat conversion [27].  
In conclusion, the data presented herein, demonstrate that aortic Akt and AMPKα 
signaling was enhanced in response to genetic deletion of myeloid-PTP1B on ApoE-/- 
background, and accompanied by increased circulating levels of the anti-inflammatory 
cytokine IL-10 and the vasodilator eicosanoid, PGE2.  Given these findings, the beneficial 
effects of PTP1B inhibition on the atherogenesis process is likely to be through an IR-
independent, PGE2/IL-10/AMPKα-driven mechanism.  Therefore, based on our data, we 
propose that PTP1B inhibitors, currently in pre-clinical trials for Type-2 diabetes and breast 
cancer [28], could be repurposed for the treatment of atherosclerosis and reduction of CVD 
risk.   
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Figure Legends 
Figure 1: Myeloid specific PTP1B deletion does not affect adiposity. (A) Western blot of 
bone marrow derived macrophages depicting deletion of PTP1B in LysM-PTP1B/ApoE-/- 
mice, GAPDH was used as a loading control. (B) Schematic representation of the 
experimental design. Mice were divided into ApoE-/- or LysM-PTP1B/ApoE-/- groups, both 
males and females were tested (n=9-13 per group). Weekly body weights of male (C) and 
female (D) cohorts. Body composition was analyzed using an Echo MRI-3-in-1 scanner 
where total body fat (E, F) or lean mass (G, H) was determined (n=9-11 per group). Data are 
represented as mean ±  S.E.M. and analyzed by Two-way ANOVA followed by Bonferonni 
multiple comparison t-tests. 
Figure 2: Myeloid specific PTP1B deletion improves glucose maintenance 
independent of weight gain in HFD fed and CHOW fed mice. Glucose tolerance tests at 
week 0, 6 and 12 of male (A, C, E) and female (B, D, F) mice fed HFD and insulin tolerance 
tests (G, H, male and female respectively) at week 11. Mice were fasted for 5h prior to basal 
glucose monitoring (as described in materials and methods) and subsequently mice injected 
I.P. with 20% glucose (w/v) or insulin (0.75mU/g body weight) and blood re-analyzed at 
15, 30, 60 and 90 mins post-injection. Blood was collected at terminal culls and serum 
analyzed for circulating insulin levels (I, J) using ELISA (Millipore). Data are represented as 
mean ±  S.E.M. (n=7 per group) and analyzed by unpaired two-tailed t-tests or two-way 
ANOVA followed by Bonferroni multiple comparison t-tests where *p≤0.05, **p≤0.01, 
****p≤0.0001 when compared to ApoE-/- control groups. 
Figure 3: Myeloid specific PTP1B deletion reduces serum cholesterol and 
triglycerides and reduces atherosclerotic plaque formation. Blood was collected at 
terminal culls and serum analyzed for circulating total cholesterol (A) triglyceride levels (B) 
using ELISA (Millipore) (C) Representative (n=5-6 per group) aortic root sections stained 
with Oil Red O. (D) Quantification of plaque area as analyzed using Image J software. 
Serum analysis of circulating IL-10 under HFD-feeding conditions (E) and PGE2 under chow-
feeding conditions (F) quantified by ELISA and lipidomics respectively. For IL-10 analysis, 
values below the level of detection were designated 0. Data are represented as mean ± 
S.E.M. and analyzed by one way ANOVA followed by unpaired two-tailed t-tests where 
*p≤0.05 and **p≤0.01 when compared to ApoE-/- control groups. 
Figure 4: Myeloid specific PTP1B deletion improves Akt and AMPK signaling in 
CHOW-fed and HFD-fed mice (A, B, F, G) Western blot analysis of aortic tissues from male 
(A, B) and female (F, G) ApoE-/- or LysM-PTP1B/ApoE-/- mice fed either chow (A, F) or HFD 
(B, G) and injected with either saline or insulin immediately prior to culling. Quantification of 
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p-IR (Tyr 1162/1163) (C, H), p-Akt (Ser 473) (D, I)  and p-AMPKα (Thr 172) (E, J) of male 
and females represented in A, B and F, G respectively. Data are represented as mean ±  
S.E.M. and analyzed by one way ANOVA followed by Dunnets post hoc analysis or unpaired 
two-tailed t-tests where *p≤0.05, **p≤0.01, ***p≤0.01  when compared to saline or ApoE-/- 
control groups. 
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Highlights 
• PTP1B inhibition as therapy for atherosclerosis/cardiovascular disease is proposed 
• Myeloid- PTP1B mice on ApoE-/- background (ApoE-/-/LysM-PTP1B) were generated 
• ApoE-/-/LysM-PTP1B had improved glucose homeostasis with no body weight 
differences 
• ApoE-/-/LysM-PTP1B had lower lipids and protection against atherosclerotic plaques 
• Protection was via a PGE2/IL-10/AMPKα mechanism  
